By Rebecca Gambler  

DHS is responsible for securing the nation’s borders against the trafficking of drugs. This includes illicit fentanyl, which continues to be the primary cause of overdose deaths in the U.S. The James M. Inhofe National Defense Authorization Act for FY 2023 requires DHS to, among other things, establish a program to collect data and develop measures to assess the effectiveness of efforts to detect and deter illicit fentanyl, including its analogues and precursor chemicals, from being trafficked into the U.S. The Act includes a provision for GAO to review the data collected and measures developed by DHS’s program. This report examines (1) DHS data on seizures of illicit fentanyl, its precursor chemicals, and production equipment from FY 2021 through 2024; (2) DHS efforts to combat the trafficking of these items into the U.S.; and (3) the extent DHS has assessed the effectiveness of its efforts. GAO analyzed DHS, CBP, and HSI documents and data on fentanyl-related seizures and investigations for FY 2021 through 2024. GAO also interviewed DHS, CBP, and HSI officials, including CBP and HSI field officials during visits to four locations. What GAO Recommends GAO recommends that DHS (1) establish a statutorily required program to collect data and develop measures to assess efforts to combat fentanyl trafficking into the U.S., (2) ensure the entity it tasks with establishing the program has access to needed information, and (3) develop performance goals and measures for its strategic goals. DHS concurred with the recommendations.  

Washington, DC: United States Government Accountability Office  - GAO, 2025. 58p.